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BACKGROUND: The natriuretic peptide hormone family
includes various proteins characterized by similar
chemical structure and shared biological functions,
with important effects on the cardiovascular system.
Accordingly, these molecules are widely recognized as
key clinical biomarkers in the diagnosis and monitor-
ing of heart failure, hypertension, and coronary heart
disease.
CONTENT: Several single-nucleotide polymorphisms
have been recently identified in genes associated with
the natriuretic system. This review provides an over-
view of new insights into the functional role of these
genetic variants, as well as their impact on cardiovas-
cular physiopathology and drug response.
CONCLUSIONS: Noteworthy relationships between some
specific polymorphisms and clinical correlates of car-
diovascular disease have emerged. Nevertheless, future
confirming studies are needed to substantiate the clin-
ical relevance of such variants.
© 2009 American Association for Clinical Chemistry
Remarkable advances have occurred since the discov-
ery of the existence of an atrial natriuretic factor
[A-type natriuretic peptide (ANP)2] in the early 1980s
by de Bold and his group (1 ). Since then, our under-
standing of the importance of the NPs has moved well
beyond awareness of their role as regulators of renal
function (2 ). Growing evidence now indicates the
strong involvement ofNPs in the control ofmyocardial
development and function as well as cardiovascular
regulation (2 ). Accordingly, application of NPs for di-
agnostic and prognostic purposes has spread in clinical
cardiology. Specifically, commercial assays for the mea-
surement of the B-type NP (BNP) and the N-terminal
portion of the B-type hormone (NT-proBNP), obtained
after cleavage of the prohormone produced by mRNA
translation, are largely available for clinical evaluation in
the cardiovascular setting (Fig. 1) (2).
Many aspects in this field remain to be elucidated,
including what determinants may affect expression,
synthesis, release, and metabolism of these peptides, as
well as what factors are involved in receptor-mediated
biological activity. Of particular interest is increasing
knowledge about the function in the natriuretic sys-
tem–related genes of single-nucleotide polymorphisms
(SNPs), which might play substantial roles in the etiol-
ogy and pharmacotherapy of cardiovascular disease.
The aim of this review is to discuss recent discoveries
and insights in this field and their potential clinical
implications.
The Natriuretic System in Cardiovascular Disease:
Basic Biochemical and Physiologic Principles
NPs are a family of hormones that includes ANP, BNP,
andC-typeNP (CNP), all presenting a similar chemical
structure and sharing biological functions (3 ).
Specifically, all NP family components are charac-
terized by the presence of a 17–amino acid ring, stabi-
lized by a cysteine bridge, with 11 of the 16 residues
being conserved in their molecular structure across the
different peptides. Two terminal amino acid tails with
widely different lengths and compositions are also
present (Fig. 2). ANP and BNP aremainly produced by
and released from cardiomyocytes (the ANP preferen-
tially from the atria and BNP from the ventricles) (3 ).
CNP, the third natriuretic peptide identified, is pri-
marily expressed in the central nervous system and vas-
cular endothelium, where it exerts autocrine and para-
crine effects on vascular tone and muscle cell growth
(2 ).
NP biological effects are mediated by 3membrane
receptors: NP receptor A, preferentially activated by
ANP and BNP, and NP receptor B, with higher affinity
forCNP thanANP andBNP, andNP receptorC,which
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is involved in the clearance of all NP from the blood
(Fig. 2) (3 ). Degradation by neutral endopeptidase
contributes to NP clearance (3 ).
All the biologically active peptides of the natri-
uretic hormone family share the same physiological
actions, including potent diuretic, natriuretic, and
vascular smooth muscle–relaxing effects, as well as
complex interactions with the hormonal, nervous,
and immunological systems (2 ). Other important
actions, all directed at protecting the cardiovascular
system from the consequences of volume and pres-
sure overload, have been identified and are summa-
rized in Table 1.
Clinical Utility of NP Testing
Since the development of the firstmethods formeasur-
ing ANP (4, 5) and the documentation of the im-
portance of the NP system in the regulation of blood
pressure, NP has been widely investigated in the physio-
pathology and treatment of hypertension. Plasma con-
centrations of NP appear lower in normotensive indi-
viduals with positive family history, whereas higher
NP concentrations are associated with better diastolic
function (6, 7 ). The possible protective role of NP in
healthy individuals is otherwise confirmed by direct
NP infusion, which improves left ventricular diastolic
performance (8, 9 ). Conversely, abnormal concentra-
tions of NP have been found in hypertensive patients
(4, 5 ). High ANP concentrations have been observed
in hypervolemic hypertension, in which ANP secretion
is primarily stimulated by atrial myocardial stretch
(10). Moreover, BNP concentration appears to in-
crease in relation to hypertension severity, particularly
in the presence of left ventricular hypertrophy, pre-
sumably due to the increase in ventricularmass and the
associated higher BNP synthesis and secretion from
ventricular tissue (2 ).
Increased concentrations of NP have been seen in
acute coronary syndromes, in which the amount of in-
crease in concentration is related to the size of the in-
farct and the extent of ventricular dysfunction (11).
Increased NP concentration is a risk factor indepen-
dent of all other traditional variables in patients with
unstable and those with stable coronary artery disease
(11, 12).Moreover, elevation ofNP concentrations is a
strong and independent adverse prognostic indicator
of heart failure (HF) or death in acute coronary syn-
drome as well as in stable coronary artery disease
(11, 12). Interestingly, increased expression of NP has
been found in human atherosclerotic vessels, suggest-
Fig. 1. Schematic representation of BNP, NT-proBNP, and the processing and secretion of precursor peptides.
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ing that the plaque may contribute to elevation of
circulating NP, plaque development, and vascular
remodeling (13).
The measurement of BNP and NT-proBNP has
emerged as an important clinical tool in the evalua-
tion and management of HF (14, 15 ). The impor-
tance of NP measurements in HF has been under-
lined in a recent metanalysis, which demonstrated
the high diagnostic accuracy and clinical relevance of
BNP and NT-proBNP assays for both acute and
chronic HF (16 ). A systematic review foundNP to be
a strong independent prognostic indicator in acute
and chronic HF (17 ).
Other clinical applications of NPs that are under
investigation include screening for asymptomatic ven-
tricular dysfunction and guiding therapy. In particular,
on the basis of observations reported to date it is rea-
sonable to expect that treatment of HF guided by BNP
and NT-proBNP concentrations could improve clini-
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Fig. 2. Schematic representation of natriuretic peptide primary structure, natriuretic peptide receptors, and ligand
selectivity.
NPR-A, NPR-B, and NPR-C, represent natriuretic peptide receptors A, B, and C, respectively GTP, guanosine triphosphate; cGMP,
cyclic guanosine monophosphate.
Table 1. Physiological effects of natriuretic peptides.
Natriuresis 
Diuresis 
Venous tone 
Arterial tone 
Cardiac and vascular hypertrophy and remodeling 
Sympathetic nerve activity 
Parasympathetic nerve activity 
Aldosterone concentration 
Fibrosis 
Renin secretion 
Glomerular filtration rate and filtration fraction 
Lipolysis 
Inflammation 
Platelet activation 
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cal outcomes, and large-scale randomized controlled
trials are currently in progress to verify the efficacy of
such treatment strategies (18–20).
The Natriuretic Precursor Peptide A Gene and Its
Polymorphisms
GENETIC LOCATION AND GENE CHARACTERISTICS
The human ANP gene, natriuretic peptide precursor A
(NPPA),3 is found on chromosome 1p36.2, in close
proximity to the BNP gene , natriuretic peptide precur-
sor B (NPPB) (NPPA is separated by 8 kb from the 5
extremity of NPPB) (Fig. 3). The ANP gene, like the
BNP gene, contains 3 exons and 2 introns (21). Exon 1
codes for the first 16 residues, exon 2 for the rest of the
amino acid sequence, except for the C-terminal ty-
rosine (21). Thus the third exon encodes for this single
residue followed by the 3 untranslated region (UTR)
of the mRNA (21).
BIOLOGICAL SIGNIFICANCE AND CLINICAL RELEVANCE
Since the beginning of the 1990s, various polymor-
phisms have been identified at this locus and associated
with various conditions (22–28). Results reported
more recently have been related to progress in the field
of cardiovascular diseases (29–42). A list of the main
SNPs of the ANP gene that have been associated with
cardiovascular disease is shown inTable 2, withmost of
these studies generally investigating the presence and
features of hypertension, diabetic nephropathy, and
ischemic stroke.
The most studied SNP is the transition T2238C
in the ANP gene, which introduces a stop codon and
leads to extension of the protein from 28 amino acids
to 30 by the addition of 2 arginines (23 ). This var-
iant has been found to be associated with nonfatal
myocardial infarction, stroke, coronary artery dis-
ease, hypertension, and left ventricular hypertrophy
(29, 34, 37 ). The functional significance of T2238C
polymorphisms has not been fully described, how-
ever, and there is no clear evidence that the minor
C-allele is associated with decreased plasma ANP
concentrations (28, 30 ).
Recently, we investigated the possible impact of
the T2238C polymorphism inHF, finding that patients
3 Human genes: NPPA, natriuretic peptide precursor A; NPPB, natriuretic peptide
precursor B; NPR1, natriuretic peptide receptor A/guanylate cyclase A (atriona-
triuretic peptide receptor A); NPR2, natriuretic peptide receptor B/guanylate
cyclase B (atrionatriuretic peptide receptor B); NPPC, natriuretic peptide pre-
cursor C; NPR3 natriuretic peptide receptor C/guanylate cyclase C (atrionatri-
uretic peptide receptor C).
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Fig. 3. Chromosome localization and organization of human ANP (NPPA), BNP (NPPB) and CNP (NPRC) genes.
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with the T allele have higher concentrations of not only
ANP but also of BNP andNT-proBNP (41). It is there-
fore plausible that the presence of the T2238C poly-
morphismmight be an additive factor influencing dis-
ease progression and prognosis in severe HF, although
these findings need further confirmation.
A recent multicenter randomized clinical trial
conducted on 38 462 participants with hypertension
revealed evidence of a pharmacogenetic association of
the ANP precursor gene T2238C variant with clinical
outcome after randomization to treatment (43). Spe-
cifically, patients who were carriers of the minor
C-allele presented better prognosis when assigned to
receive a diuretic, whereas patients carrying TT had
fewer adverse events when randomized to receive a
calcium-channel blocker (43). These findings suggest
that individuals with a higher-risk genotype would
have more favorable outcomes when taking a diuretic
compared with their counterparts taking other classes
of antihypertensive medications (43). Further studies
are needed to better define the physiologic effects of
T2238C before introducing into clinical practice indi-
vidualized treatment based on genetic testing prior to
medication administration.
TheNPPBGene and Its Polymorphisms
GENETIC LOCATION AND GENE CHARACTERISTICS
The human BNP gene, NPPB, is located on chromo-
some 1p36.2 and contains 3 exons and 2 introns (Fig.
3). The complete nucleotide sequence of BNP was first
described at the end of the 1980s (44). Exon 1 of the
human BNP gene encoded the 5 UTR and a part of
preproBNP (the 26–amino acid signal peptide and the
first 18 amino acids of proBNP); exon 2, the amino
acids from 45 to129; and exon 3, the 5 terminal amino
acids (from 130 to134) and the 3 UTR (44). Several
years later, the 5 flanking region located upstream
from a UTR was described (45).
BIOLOGICAL SIGNIFICANCE AND CLINICAL RELEVANCE
In the past, very few studies have explored the role of
SNPs of the BNP gene in the pathogenesis and devel-
opment of diseases. In 2000, the CARDIGENE study
evaluated a possible association between the nucleotide
substitution C-1563T in the BNP gene and the predis-
position to idiopathic dilated cardiomyopathy, but
study results did not indicate any relationship between
this SNP and susceptibility to this disease (46).
Subsequently, a microsatellite marker localized
within the 3 end of the BNP gene was analyzed in a
population of essential hypertensive patients to evalu-
ate any possible association with hypertension-related
modification of the left ventricle as assessed by echo-
cardiography (29). The findings showed no significant
effect of BNP gene variants on ventricular remodeling
in human essential hypertension.
A very recent study evaluated the association be-
tween the BNP promoter T–381C polymorphism and
risk of type 2 diabetes and metabolic and BNP expres-
sion traits in samples from several populations. The
study included participants of the MONICA (Moni-
toring Trends and Determinants in Cardiovascular
Disease) study and 4 other case–control studies, for a
total of 3593 cases and 6646 controls (47). The re-
sults indicated that individuals carrying the –381CC
Table 2. More common SNPs in the NPPA gene.
Variant
Restriction
site Position Mutation References
T2238C ScaI Exon 3 Stop codon loss: protein extended from
28 to 30 amino acids
Rubattu et al. (27 ), Nannipieri et al.
(28 ), Rubattu et al. (29 ), Nannipieri
et al. (31 ), Rahmutula et al. (32 ),
Gruchala et al. (34 ), Nannipieri
et al. (35 ), Roussell et al. (36 ),
Rubattu et al. (37 ), Conen et al.
(39 ), Vassalle et al. (41 )
G664A RsaI 5 UTR Vat7Met substitution Rubattu et al. (29 ), Kato et al. (30 ),
Rahmutula et al. (32 ), Kato et al.
(33 ), Rubattu et al. (37 ), Zhang
et al. (38 ), Conen et al. (39 ),
Iemitsu et al. (42 )
C708T BstXI Intron 1 Nannipieri et al. (28 ), Nannipieri et al.
(31 ), Nannipieri et al. (35 ), Roussell
et al. (36 )
G1837A SmaI Intron 2 Rubattu et al. (27 ), Rubattu et al.
(29 ), Rahmutula et al. (32 ),
Rubattu et al. (37 )
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genotype presented lower concentrations of plasma glu-
cose and lower risk of type 2 diabetes. Moreover, the
–381C allele was associated with higher BNP concentra-
tion and higher BNP promoter activity in reporter gene
assays. Interestingly, BNP concentrations were found to
beparticularly increased in–381Callele carriers evaluated
in a subpopulation of stable HF patients (47).
Eight polymorphisms in NPPB, including the
T–381C variant, and their association with BNP con-
centrations were also evaluated in a large general
population of adult Japanese persons, revealing sig-
nificant associations of the variants with BNP con-
centration (48). In this study, both single-SNP analysis
and haplotype-based analysis revealed an association
between the presence of NPPB SNPs with circulat-
ing BNP concentrations. In particular, the findings
for the promoter SNP T–381C showed a codominant
effect of the minor C-allele on elevating plasma BNP
concentrations.
These findings suggest a functional role for the
T–381C variant that may lead to changes in the predic-
tive use of BNP for diagnosis and prognosis. In another
study in a selected population of patients undergoing
elective cardiac catheterization, the T–381C variants
were evaluated together with the NPPB 777 GA (3
flanking region) and other variants of 5 genes involved
in the BNP pathway (49). The results of this study in-
dicated that individuals who carried the TT variant had
lower BNP concentrations.
The association between 2 polymorphisms
(–381T/C and 1551G/A) of the BNP gene was also as-
sessed according to NT-proBNP concentrations and
mortality in 380 type 1 diabetic patients with andwithout
diabetic nephropathy (50). Carriers of the –381T/C and
1551G/A polymorphisms had higher concentrations of
NT-proBNP without presenting prevalent overt diabetic
nephropathy. These variants did not predict all-cause or
cardiovascular mortality in type 1 diabetic patients with
or without diabetic nephropathy.
Finally, a novel variable number of tandem repeat
(VNTR) polymorphism in the 5 flanking region of the
NPPB gene was discovered. This polymorphism was
associated with essential hypertension in female pa-
tients (51).
Natriuretic Peptide Receptor C/Guanylate Cyclase C
(Atrionatriuretic Peptide Receptor C) Gene and Its
Polymorphisms
GENETIC LOCATION AND GENE CHARACTERISTICS
The human natriuretic peptide receptor C/guanylate
cyclase C (atrionatriuretic peptide receptor C) (NPR3)
gene is located on chromosome 5p14-p13 (55). It
spans approximately 70 kb, and contains 8 exons and
7 introns (Fig. 3) (52).
Several polymorphisms in the NPR3 gene have
been described, including the C(–55)A polymorphism
in the promoter region of the NPR3 gene and a VNTR
polymorphism consisting of a 6-nucleotide repeat 4
bp upstream from the major transcriptional initia-
tion site in the 5 flanking region of the NPR3 gene
(49, 41, 42, 52–57 ).
BIOLOGICAL SIGNIFICANCE AND CLINICAL RELEVANCE
TheC(–55)A and theVNTRpolymorphisms have been
found to be associated with hypertension and obese
hypertension; C(–55)A is also related to lower ANP
concentrations and higher systolic and mean blood
pressure (53, 56).
Moreover, C-allele carriers in a general population
were found to have significantly lower prevalence of
overweight, obesity, and abdominal adiposity com-
paredwith the A(–55)A carriers (57). TheC(–55) allele
of the NPR3 gene was found also to be associated with
family history of hypertension (54). However, our re-
cent data did not show the C(–55) NPR3 polymor-
phism to be an independent determinant of NP con-
centration in HF (41).
Genes and Polymorphisms Relative to Other
Members of the Natriuretic System
GENETIC LOCATIONS AND GENE CHARACTERISTICS
The natriuretic peptide receptor A/guanylate cyclase A
(atrionatriuretic peptide receptor A) (NPR1) gene is lo-
cated on chromosome 1q21–22 and has a similar struc-
ture to the natriuretic peptide receptor B/guanylate cy-
claseB (atrionatriuretic peptide receptorB) (NPR2) gene,
the latter located at 9p21-p12 (58, 59). These genes are
about 16 kb long, and they have 64% cDNA homology
(58). They are composed of 22 exons each (58).
The gene encoding CNP, natriuretic peptide pre-
cursor C (NPPC), is localized to human chromosome 2
and consists of 2 exons separated by 1 intron (60).
BIOLOGICAL SIGNIFICANCE AND CLINICAL RELEVANCE
Some polymorphic sites were identified in the NPR1
gene, especially in the 5-flanking region and other
noncoding regions, that may influence the transcrip-
tional activity of the gene and may be thus potentially
involved in the pathogenesis of essential hypertension
and other cardiovascular disease (37, 54, 61–68).
In the Japanese population, an 8-bp deletion in the
5 flanking region of NPR1 was found to be associated
with essential hypertension and left ventricular hyper-
trophy (62). In another study by the same authors, a
missense mutation, M341I, consisting of a methionine
(ATG) to isoleucine (ATC) substitution at nucleotide
1023 in exon 3, was identified and shown to be associ-
ated with essential hypertension (63 ). Amino acid
residue 341 is in the loop between 2 -helices, and
therefore the M341I substitution may change the con-
NP Genetic Variants Reviews
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formation of the hydrophobic core, influencing recep-
tor activity (63). Interestingly, theM341I SNPwas also
reported to be associated with higher risk for myocar-
dial infarction in the Japanese population (64).
The 8-bp deletion in the 5 flanking region was
also evaluated in an Italian population, in which this
microsatellitemarker of theNPR1 genewas found to be
significantly associated with left ventricularmass index
and left ventricular septal thickness, suggesting that the
functional relevance of the mutant alleles may be re-
lated to a reduced NP receptor A activity (29).
Recently, Knowles et al. sequenced the entire hu-
manNPR1 gene and identified the (CT)n dinucleotide
repeat site (n 6, 10, or 11) at nucleotide293 in the
promoter region as well as 9 other polymorphic sites in
the noncoding region of the gene (66). In particular, 3
common haplotypes in the 5 and 3 regions of the
receptor gene have been identified, and 3 of these have
been shown to have quantitative effects on the expres-
sion of the receptor in vitro (66).
These haplotypes in the NPR1 gene have been re-
cently evaluated in 402 unrelated white individuals, in-
cluding healthy controls and patients with acute coro-
nary syndrome and HF (67). Results indicated that the
“4-minus” haplotype of the NPR1 gene is related to
high NT-proBNP concentration and represents a ge-
netic determinant of between-person variability in the
BNP system in healthy individuals but not in patients
with cardiovascular diseases.
The (CT)n polymorphism in the 5-flanking re-
gion of the NPR1 gene also was found to be signifi-
cantly associated with essential hypertension, probably
through the downregulation of NPR1 gene transcrip-
tion (68). However, the authors did not observe any
significant association between the 8-bp deletion in the
5 UTR and essential hypertension (68).
The structural organization of the human NPR2
gene was studied, and several polymorphic sites were
found in NPR2, including a GT-repeat polymorphism
in intron 2, a C2077T transition in exon 11, and a 9-bp
deletion in intron 18 (59, 69–71). These studies showed
that theGT-repeat polymorphismwas associatedwith es-
sential hypertension, whereas the I/D deletion did not
show any significant relationship either with this condi-
tionorwith stroke (59, 69, 70). In addition,no significant
association was found between the C2077T polymor-
phism andmyocardial infarction (71).
To our knowledge, there is only a single report that
focuses on the associations between CNP, its genetic
variants, and blood pressure (72). Specifically, 4 ge-
netic variants have been identified in the CNP gene
(NPPC). The G2628A variant in the 3UTR of the gene
was found to be associated with essential hypertension in
a Japanese population (72). Accordingly, investigation of
the association between this genetic variant and the pres-
ence of hypertension in other populations is necessary.
Critical Remarks and Future Perspectives
In summary, growing evidence indicates that specific
genetic factors may result in altered properties in the
NP system that influence the risk for cardiovascular
disease and/or response to drug treatments.
Specifically, some noteworthy relationships have
emerged, and evidence of potentially important roles
exists for the ANP precursor gene T2238C variant, the
–T381C polymorphism in the BNP promoter, and the
(CT)n polymorphism in the NPR1 gene, as summa-
rized in Table 3.
The effect of a single sequence variant might be
small, however, and many association studies suffer
from a lack of adequate power because of small sample
size. The number of individuals needed to achieve ad-
equate power is dependent on the frequency of the
polymorphism, and a small effect will require much
larger sample sizes to detect a difference, especially if
the SNP is rare (73). For instance, a sample size of
about 700 cases and 2100 controls is needed to detect a
minimum odds ratio of 1.3 in a study with an allele
frequency of 30%,with a power of 80%at a significance
of 95% (74).
When these factors are taken into account, it is
clear that few of the studies listed in Table 3 were suf-
ficiently powered. Therefore, additional data are
needed to test the possible contribution of each SNP
and potential gene–gene interaction to the susceptibil-
ity for heart disease. Future studies should test the si-
multaneous genotyping of the ANP precursor gene
T2238C variant, the –T381C polymorphism in the
BNP promoter, and the (CT)n polymorphism in the
NPR1 gene. Moreover, further efforts should also in-
volve collaborations to increase population sizes and
maximize power. Several issuesmust be carefully man-
aged during the design of such studies, including defi-
nition of the phenotype, selection of controls, mea-
surement of plasma concentrations of NPs, and
adjustment for multiple comparisons and population
stratification.
With respect to pharmacogenetics, it is widely ex-
pected that in the future drug treatment will be strati-
fied on the basis of genetic information. Gene–drug
interactions are complex, but between-person varia-
tion in drug responses to treatments appears in many
cases to have a simpler genetic basis than that found for
common diseases (75). Thus it is crucial to integrate
evidence across studies because it is likely that multiple
genes operating in pathwayswill determine response to
pharmacological treatment.
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Actually, a paucity of information is available re-
garding interactions of NP genes with the effects of
standard therapies. Well-conducted clinical studies
will be required to evaluate the impact of selected gene
variants on the efficacy of a drug treatment as well as on
the risk for adverse outcomes.
A potential experimental design strategy for these
studies is the limitation of assessed cases to only those
cases nested within randomized controlled trials; such
a “case-only” designwould provide a possiblemeans to
decrease the cost of genotyping when dichotomous
outcomes are being investigated (76, 77). In epidemi-
ology and genetics, there is a growing literature about
case-only study designs as a means of investigating
gene–environment interaction in disease etiology (78–
80). In the pharmacogenetic context, environmental
exposure would correspond to the treatment and ge-
notype to the covariate. The outcome of interest would
have to be dichotomous, and study participants who
develop this outcome during follow-up would be de-
fined as cases (78, 79).
By design, genotype and treatment are indepen-
dent, because the latter is randomly allocated within
controlled clinical trials. As a result, the case-only odds
ratio is also a measure of gene–treatment interaction
(78, 79). Such an approach may be especially suitable
for studying gene–drug interactions, providing greater
statistical power than a case–control study of the same
sample size.
In conclusion, the complexity of the NP system
requires more appropriate investigations with very
large sample sizes and robust genetic approaches, such
as the use of high-throughput genotyping platforms, to
improve the understanding of gene–gene interactions
of NP proteins and related neurohormonal pathways.
Nonetheless, the identification and characterization of
functional SNPs that influence NP activity is surely an
important research goal toward integrating DNA-
based testing into clinical strategies for diagnosis and
personalized treatment of at-risk individuals.
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Table 3. Possible functional SNPs of the NP system in cardiovascular disease.
Gene variant Ethnicity Study population
SNP–disease
association
NP levels–SNP
association Ref.
NPPA T2238C White Stroke/controls (n  347/346) No Not reported Rubattu et al. (27 )
White Stroke/controls (n  206/236) Yes Not reported Rubattu et al. (37 )
White T1 DMa/controls (n  454/58) Yes ANP levels A2A2A2A1 Nannipieri et al. (28 )
White DM/EH/controls (n  807/121/105) Yes Not reported Nannipieri et al. (31 )
Mexican T2 DM/EH/controls (n  112/191/985) Yes Not reported Nannipieri et al. (35 )
Japanese EH/controls (n  233/213) No Not reported Rahmutula et al. (32 )
White MI/noMI (n  504/340) Yes Not reported Gruchala et al. (34 )
White CAD severity (n  847) Yes Not reported Gruchala et al. (34 )
White T1 DM with/without DN (n  489/301) Yes Not reported Roussell et al. (36 )
White HF severity (n  124) — ANP, BNP and
NT-proBNP
A2A2A1allele
Vassalle et al. (41 )
NPPB T-381C White T2 DM/controls (n  3331/4161) Yes BNP levels TTTCCC Meirhaeghe et al. (47 )
Japanese General population (n  2970) — BNP levels TTTCCC Takeishi et al. (48 )
African/white Elective cardiac catheterized pts (n  147) — BNP levels TTTCCC Lanfear et al. (49 )
African/white T1 DM with/without DN (n  197/183) No NTpro-BNP levels
TTTCCC
Layer et al. (50 )
NPRA (CT)6 Japanese EH/controls (n  177/170) Yes No Usami et al. (68 )
a T1 DM, type 1 diabetes mellitus; EH, essential hypertension; T2 DM, type 2 DM; MI, myocardial infarction; CAD, coronary artery disease; DN, diabetic nephropathy.
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